LCS Therapeutics announced today that it has entered into a strategic collaboration with Lucerne Biosciences, LLC ("Lucerne Biosciences") to commercialize U.S. Patent No. 8,318,813 entitled "Method of Treating Binge Eating Disorder." Patent '813 features claims that encompass the use of the amphetamine prodrug lisdexamfetamine dimesylate (l-lysine-d-amphetamine) alone, or in combination with other pharmacologic therapies, for the treatment of Binge Eating Disorder (BED) according to its current diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V®).
"This strategic collaboration with Lucerne Biosciences marks an important step forward in bringing much needed public attention to the diagnosis and treatment of BED. BED is a serious eating disorder currently without any FDA-approved medication treatments and for which, unfortunately, there have been many public misconceptions. Developing safe and effective treatments for eating disorders more generally, and for BED in particular, continues to be a critically important unmet need long-recognized in the medical community," said Louis Sanfilippo, M.D., CEO of LCS Therapeutics.
"Recent studies show that between 2 to 3% of the U.S. population will suffer from BED at some point in their lifetime and many of these patients will have a chronic course of symptoms with significant burdens to their emotional and physical health," said Dr. Sanfilippo, who also is a voluntary faculty member at Yale University School of Medicine and teaches psychopharmacology to psychiatry residents.